X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Celgene logo on computer screen. Courtesy photo.

Drugmaker Celgene has agreed to pay $55 million to settle a class action lawsuit accusing it of violating antitrust laws by interfering with the development of generic versions of two of its cancer drugs.

This premium content is locked for
Delaware Business Court Insider subscribers only.

*May exclude premium content
Already have an account?
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to groupsales@alm.com to learn more.

Charles Toutant

Charles Toutant is a litigation writer for the New Jersey Law Journal.

More from this author

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.